USTMA is committed to fostering collaboration and forming a true alliance with other advocacy organizations to improve the lives of individuals affected by thrombotic microangiopathy (TMA) in the US. By sharing resources and pooling expertise, USTMA advocates for enhanced care and treatment options, while supporting vital research initiatives.
2018
83-1768842
$797.3 thousand
Thrombotic microangiopathies are rare but severe conditions that cause organ damage. USTMA raises awareness about these diseases.
USTMA provides valuable resources for patients, including access to patient ambassadors and advisories.
Join USTMA for the 2024 Patient Meeting in Dallas, Texas, focused on community support and education.
December 6, 2024
A workshop dedicated to advancing TMA research and clinical insights.
Learn MoreAugust 16-18, 2024
Annual meeting to foster community among TMA patients.
Learn MoreDecember 8, 2023
Discussion focused on TMA among physicians.
Learn MoreOverall Score
39
26
/100
Program Expense Ratio
54.78%
4
/20
Program Revenue Growth
-100.00%
2
/20
Leverage Ratio
0
2
/20
Working Capital Ratio
2.652
16
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 949.3K | 99.91% |
Program Services | 0 | 0.00% |
Investment Income | 461 | 0.05% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 361 | 0.04% |
Total Revenue | 950.1K | 100.00% |
Health Associations
Cardiovascular HealthHealth Associations
Cardiovascular HealthHealth Associations
Cardiovascular HealthHealth Associations
Cardiovascular HealthHealth Associations
Cardiovascular Health